Biocon

Biocon was founded in 1978 with Rs.10,000 as the initial capital.

1979 - Becomes the first Indian company to manufacture and export enzymes to the US and Europe.

1989 - Unilever acquires Biocon Biochemicals Ltd. in Ireland and merges it with its subsidiary, Quest International; Biocon receives US funding for proprietary technologies.

1994 - Establishes Syngene International Pvt. Ltd. as a Custom Research Company .

1998 - Unilever agrees to sell its shareholding in Biocon to the Indian promoters. Biocon becomes an independent entity.

2001 - Becomes the first Indian company to be approved by USFDA for the manufacture of lovastatin; PlaFractor is granted a US 2001 and worldwide patent.

2003 - Biocon becomes the first company worldwide to develop human insulin on a Pichia expression system.

2006 - BIOMAb EGFR, first indigenously developed humanised monoclonal antibody for head-and-neck cancer is launched and Dr. APJ Abdul Kalam inaugurates India's Largest Biotech-Hub "Biocon Park".

* 2008 - Biocon acquires a 70% stake in German pharmaceutical company, AxiCorp GmbH.

2009 - Syngene-Bristol Myers Squibb research facility is established in Bengaluru.

2009 - Mylan announces strategic collaboration with Biocon to Enter the Global Generic Biologics Market.

2010 - Biocon expands to Malaysia, biopharmaceutical manufacturing and R&D facility established in Iskandar Malaysia, Johor.

2011 - Biocon launches INSUPen®, a convenient and affordable reusable insulin delivery device.

2012 - Abbott announces collaboration with Syngene to Open First Nutrition R&D Center in India.

2013 - Biocon launches biologic drug ALZUMAb to treat psoriasis.

2014 - Biocon launches world's first biosimilar drug CANMAb to treat breast cancer.

2015 - Biocon launches hepatitis-C drug in India under brand name CIMIVIR-L.

2016 - Becomes the first Indian company to launch a biosimilar Insulin Glargine pen in Japan.

2016 - Syngene sets up Amgen R&D center in Bangalore.

2017 - Biocon's Insugen is the first locally manufactured biosimilar product to be approved for sale by the Malaysian drug regulator.

2017 - USFDA approves Mylan-Biocon's biosimilar for cancer drug Herceptin.

2018 - Biocon, Mylan get European Commission approval to market biosimilar insulin glargine.

2021 - Biocon Biologics and Serum Institute of India formed a joint agreement to commercialise vaccines, biological drugs, and antibody therapies together. Another aspect of the deal involves Bicocon selling 15% of its biologics subsidiary to Serum Institute of India, in return for Biocon gaining access to 100 million annual doses of vaccines for a 15-year period.

2022 - Biocon Biologics buys the biosimilar assets of Viatris, for $3.34 billion.